The objective of the present study was to estimate the effectiveness of the long-term treatment with low doses of macrolides for the prevention of early relapses of polypous rhinosinusitis in the postoperative period. A total of 66 patients at the age from 18 to 77 years presenting with the clinical diagnosis of bilateral polypous rhinosinusitis were randomly allocated to 3 groups; fifty five patients completed the study. All the patients underwent endoscopic polysinusotomy. All of them were given basal therapy with mometasone furoate at a daily dose of 400 mcg throughout 6 month postoperative period. The patients of groups 1 (n=22) and 2 (n=14) additionally received daily doses of 25 mg clarithromycin during 6 and 3 months respectively. The patients of group 3 were given basal therapy alone. All the patients were followed up within 6, 12, and 24 weeks after surgery with the use of a visual-analog scale, SNOT-20 questionnaire, acoustic rhinometry and rhinomanometry, endoscopic study of the nasal cavity, computed tomography of paranasal sinuses, determination of saccharine transport time, evaluation of olfactorial sense, and measurement of the eosinophilic cationic protein level in the nasal secretion. It was demonstrated that the patients treated with clarithromycin show significantly better outcomes of therapy compared with controls (p<0.05), the effectiveness of the 6 month clarithromycin therapy being higher than that of the 3 month treatment. The exception was the results of estimation of clinical symptoms and signs based on the visual-analog scale and the acoustic rhinometric data that did not reveal significant differences between the groups. The patients of the control group given no clarithromycin significantly more frequently developed relapses of polypous rhinosinusitis (p=0.02).

Download full-text PDF

Source

Publication Analysis

Top Keywords

polypous rhinosinusitis
12
effectiveness long-term
8
long-term treatment
8
low doses
8
postoperative period
8
basal therapy
8
patients
7
[the effectiveness
4
treatment polypous
4
rhinosinusitis low
4

Similar Publications

Objectives: To identify the risk factors for postoperative relapse of chronic rhinosinusitis with nasal polyps (CRSwNP) using multivariate Logistic regression analysis and to explore potential improvements in clinical treatment measures.

Methods: We selected 270 CRSwNP patients who underwent surgery at The First People's Hospital of Jiangxia District between January 2022 and July 2024. The patients were divided into two groups based on the presence or absence of postoperative relapse: 40 cases with relapse were designated as the relapse group, and the other 230 cases without relapse were designated as the non-relapse group.

View Article and Find Full Text PDF

Objective: This study seeks to elucidate the role and molecular mechanisms of IL-8 in nasal epithelial cell pyroptosis and its impact on glucocorticoid (GC) resistance.

Methods: We assessed the expression of pyroptosis-related biomarkers and IL-8 in tissues and human nasal epithelial cells (hNECs) from both control and nasal polyp patients using western blot. Their localization was determined through immunohistochemistry and immunofluorescence.

View Article and Find Full Text PDF

GZMK-expressing CD8 T cells promote recurrent airway inflammatory diseases.

Nature

January 2025

Laboratory of Dynamic Immunobiology, Institute for Immunology, Tsinghua University, Beijing, China.

Inflammatory diseases are often chronic and recurrent, and current treatments do not typically remove underlying disease drivers. T cells participate in a wide range of inflammatory diseases such as psoriasis, Crohn's disease, oesophagitis and multiple sclerosis, and clonally expanded antigen-specific T cells may contribute to disease chronicity and recurrence, in part by forming persistent pathogenic memory. Chronic rhinosinusitis and asthma are inflammatory airway diseases that often present as comorbidities.

View Article and Find Full Text PDF

Long-Term Effectiveness of Dupilumab in Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Multicenter Retrospective Study.

Am J Rhinol Allergy

January 2025

Otorhinolaryngology Head and Neck Surgery Department, IRCCS Arcispedale Santamaria Nuova, Reggio Emilia, Italy.

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex immunological disease associated with significant morbidity and reduced health-related quality of life. Dupilumab is an anti-T2-inflammatory biological drug registered for chronic rhinosinusitis with nasal polyps, indicated by integrated care pathways when optimal medico-surgical treatment yields insufficient control of sinonasal symptoms.

Objective: The purpose of this study was to confirm the long-term efficacy of dupilumab in the treatment of severe uncontrolled CRSwNP.

View Article and Find Full Text PDF

Patient preferences for treatment of chronic rhinosinusitis with nasal polyps.

Rhinology

December 2024

Department of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, NC, USA.

Choosing between revision endoscopic sinus surgery (ESS) versus biologic therapy for recurrent chronic rhinosinusitis with nasal polyposis (CRSwNP) is a complex, multifaceted decision that involves not only clinical and financial factors but also patient preferences. Currently, there are no quantitative studies investigating patient preferences for CRSwNP treatment options. Increased awareness of patient-centered approaches to treatment warrant further investigation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!